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It is not clear how hepatitis B virus (HBV) modulates host immunity during chronic infection. In addition to the key mediators of
inflammatory response in viral infection, monocytes also express a high-level IFN-stimulated gene, CH25H, upon response to IFN-a
exerting an antiviral effect. In this study, the mechanism by which HBV manipulates IFN signaling in human monocytes was
investigated. We observed that monocytes from chronic hepatitis B patients express lower levels of IFN signaling/stimulated genes
and higher levels of inflammatory cytokines compared with healthy donors. HBV induces monocyte production of inflammatory
cytokines via TLR2/MyD88/NF-kB signaling and STAT1-Ser727 phosphorylation and inhibits IFN-a–induced stat1, stat2, and
ch25h expression through the inhibition of STAT1-Tyr701 phosphorylation and in an IL-10–dependent, partially autocrine
manner. Further, we found that enhancement of STAT1 activity with a small molecule (2-NP) rescued HBV-mediated inhibition
of IFN signaling and counteracted the induction of inflammatory cytokines. In conclusion, HBV contributes to the monocyte
inflammatory response but inhibits their IFN-a/b responsiveness to impair antiviral innate immunity. These effects are mediated
via differential phosphorylation of Tyr701 and Ser727 of STAT1. The Journal of Immunology, 2019, 202: 2266–2275.
A
lthough an effective vaccine has been in use for decades,
over 240 million people in the world are chronically
infected with hepatitis B virus (HBV), and new infec-
tions continue to occur (1–3). HBV is an infection in which
chronic liver inflammation coexists with impaired antiviral im-
munity. The functionality of many immune cells is impacted, in-
cluding monocytes, but the molecular details of such impairment
are not well understood.
HBV infects hepatocytes of the human liver and initiates virus
replication to release HBV virions, HBVe Ag (HBeAg), and HBV
surface Ag (HBsAg). The serum levels of HBsAg, HBeAg, and
HBV DNA may fluctuate over time and are a reflection of disease
activity to define the natural course of chronic HBV infection (4–6).
During HBV infection, the virus exposes a number of pathogen-
associated molecular patterns to be recognized by pattern recog-
nition receptors located on the cell membrane, such as TLR.
Circulating monocytes express a variety of pattern recognition
receptors, so it is likely that the function of these cells will be
affected. Monocytes represent ∼10% of leukocytes in human pe-
ripheral blood and also reside in or pass through the liver as
precursors of dendritic cells and macrophages. The frequency and
number of CD14+/CD16+ monocytes in immune active chronic
hepatitis B (CHB) patients were significantly increased (7), and
their positive correlation with alanine amino transferase (ALT)
suggested a potential role contributing to liver inflammation (8).
However, the role of HBV infection in monocytes remains con-
troversial. It has been reported that HBsAg induces TNF-a and
IL-10 production of monocytes (9, 10), suggesting that HBsAg
can potentially trigger TLR activation through its association with
CD14 (11). The arginine-rich domain of the core protein was
shown to bind the macrophage-like cell line, THP-1, in a heparin
sulfate–dependent manner and trigger signaling through TLR-2
(12). But others have reported that exposure of monocytes to
HBsAg suppresses LPS-induced TNF and IL-1b production (13).
Type I IFNs (IFN-I), produced by cells infected with viruses and
some sentinel cells of the innate immune system, play a crucial role
in defense against viral infections by inducing the expression of
IFN-stimulated genes (ISGs) such as cholesterol 25-hydroxylase
(ch25h) (14–17). CH25H can be expressed at high levels in
monocytes and macrophages activated by IFN-I via STAT1 and
synthesizes 25HC to exert an antiviral effect (18–20). Monocytes
interact with the virus to produce proinflammatory cytokines and
IFN-I and to initiate immune responses to control infection.
Most vertical transmission of HBV from mother to child often
leads to chronic infection, whereas horizontal transmission be-
tween adults often leads to self-limited acute infection. It has been
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demonstrated that Kupffer cells from nontransgenic offspring of
HBV transgenic mothers that have been exposed to HBeAg in
utero express a higher level of PD-L1 to exhaust the function of
CTLs. But Kupffer cells from nontransgenic adult mice that were
never exposed to HBeAg generate efficient immunity to control
HBV infection (21). More recently, we reported that both HBV
and HBsAg induce immune suppressive monocytes to initiate
regulatory NK cell differentiation, resulting in T cell inhibi-
tion (22). We thus postulated that HBV develops sophisticated
strategies to counteract this defense, as it established de novo
infection.
We now show that the HBV-induced antagonism between in-
flammation and antiviral immunity can be studied in vitro. HBV
activates TLR2/NF-kB signaling and STAT1-Ser727 phosphory-
lation to induce the production of inflammatory cytokines and to
make a concerted attack on the IFN signaling pathway manifest
both as reduced transcription of STAT1 and STAT2 genes and in
aberrant STAT1 phosphorylation.
Materials and Methods
Human subjects
Thirty-six treatment-naive CHB patients in hospital, which were identi-
fied as immune active phase based on sera levels of HBV DNA, HBeAg,
HBsAg, and ALT, and 30 healthy donors were enrolled in this study
(Table I). All studies were conducted according to the experimental
practices and standards that were approved by the Medical Ethics Com-
mittee of The First Hospital of Jilin University (approval code 2015-125).
Written informed consent was obtained from all adult participants, and
no children were involved in this study. There were no hepatitis D virus
coinfected in any of the patients. All experiments were carried out in ac-
cordance with the approved guidelines and regulations.
Reagent
HBsAg was purchased from Meridian (catalog no. R36100), which was
purified from human plasma with the purification .95% and dissolved in
the following buffer: 0.02 M sodium phosphate, pH 7.2. Human serum
albumin (HSA) purified from healthy person serum was purchased from
ProSpec (catalog no. PRO-354). Human TLR2 Ab (catalog no. MAB2616),
human TLR4 Ab (catalog no. AF1478), and human recombinant IFN-a
(catalog no. 11200-1) were purchased from R&D Systems. Anti-human
CD282 (TLR2) FITC was purchased from eBioscience (catalog no.
11-9922-41). Human IL-10 Ab (catalog no. MAB2171), human IL-1b/IL-
1F2 Ab (catalog no. MAB201), and human TNF-a Ab (catalog no.
MAB210) were purchased from R&D Systems. Abs against MyD88 and
p-STAT2 (Tyr690) were purchased from Abcam. Protease/Phosphatase In-
hibitor Cocktail and Abs against p-STAT1 (Tyr701 and Ser727), STAT1,
STAT2, p-IkBa, IkBa, and TRAF6 were purchased from Cell Signaling
Technology (Danvers, MA). CH25H Ab was purchased from Santa Cruz
catalog no. sc-293256). BAY-11-7085 was purchased from Medchem Ex-
press (catalog no. HY-10257). 2-(1,8-naphthyridin-2-yl)phenol (2-NP) was
purchased from Sigma-Aldrich (catalog no. N2040).
Purification of cell-cultured HBV
HepG2 cells and HepG2.2.15 cells purchased from American Type Culture
Collection were maintained in DMEM medium (Corning Life Science,
Lowell, MA) with 10% FBS, penicillin, streptomycin, and glutamine. HBV
particles were collected and purified from the supernatant of HepG2.2.15
cells as described previously with modification (23, 24). Briefly,
HepG2.2.15 cells and HepG2 cells were cultured in 75T flasks in DMEM
complete medium to induce HBV replication and virion production; su-
pernatant was collected every other day with culture medium replenish-
ment for 18 d. The pooled supernatant was mixed with polyethylene glycol
(PEG)-8000 powder (Sigma-Aldrich, final concentration of 10%) and
gently rotated at 4˚C for overnight; HBV particles were then precipitated
by centrifugation at 10,000 3 g for 45 min at 4˚C and redissolved in
serum-free DMEM medium with 1% vol of the original supernatant
samples. HBV virion stocks, which were measured using the COBAS
AmpliPrep/COBAS TaqMan assay (Roche Molecular Diagnostics, Grenzach,
Germany) for viral load and ELISA for encoded proteins were aliquoted and
stored at 280˚C. The supernatant of HepG2 cell has been treated with
PEG8000 and concentrated in the same way as cell-cultured HBV (HBVcc)
stock, then used as mock control.
Limulus amebocyte assay for LPS contamination
Endotoxic contamination of HBsAg and HBVcc was assessed using
QCL-1000 chromogenic end point assay (Combrex, Cottonwood, AZ) and
found to be ,1 pg/ml.
Cell isolation and purification
PBMCs were freshly isolated from peripheral blood of healthy individuals
and CHB patients by Ficoll density gradient separation. Monocytes were
then purified by magnetic cell sorting with CD14 microbeads (Miltenyi
Biotec, Bergisch Gladbach, Germany) according to the manufacturer’s
instructions. The purity of the CD14+ cells was equal or.95% determined
by flow cytometry.
Cell culture
Purified monocytes were cultured with HBsAg, HBVcc, and/or IFN-a
(concentrations are given in the figure legends) in 96-well plates con-
taining 200 ml of complete medium (RPMI 1640, 10% FBS, penicillin,
streptomycin, and glutamine) at 37˚C in the presence of 5% CO2 for 12 or
24 h. Cells were collected for quantitative real-time PCR (qRT-PCR),
Western blot, FACS analysis, and the supernatants were harvested for
cytokine detection by ELISA.
RNA extraction and qRT-PCR
Total RNA was extracted from cells using EasyPure RNA Kit (TransGen
Biotech, Beijing, China) and then converted to first-strand cDNA using
TransScript First-Strand cDNA Synthesis SuperMix (TransGen Biotech).
Real-time PCR was performed with Power SYBR Green PCR Master Mix
(TransGen Biotech) in an ABI StepOne Plus Real-Time PCR system
(Applied Biosystems). Housekeeping gene GAPDH was used as an internal
control for quantitation, respectively. The sequences of gene-specific pri-
mers used for qRT-PCR are listed in Supplemental Table I.
Immunoblotting
Immunoblotting was carried out as described previously (25). Briefly, cells
were collected and lysed by adding lysis buffer (RIPA buffer) together with
Protease/Phosphatase Inhibitor Cocktail on ice for 30 min and tapping
tubes every 10 min. Protein concentration was quantified by Coomassie
Plus protein assay Reagent (Thermo Fisher Scientific). The quantitation of
immunoblotting band intensity was carried out with ChemiDoc XRS+
Molecular Imager software (Bio-Rad). Samples were separated by SDS–
PAGE and transferred to PVDF membranes. After blocking in PBS con-
taining 0.1% Tween-20 and 5% skim milk, the blots were probed with
relative Abs.
STAT1 knockout and mutation
STAT1 knockout (KO) of THP1 cells was carried out by CRISPR/Cas9 as
described previously (26, 27). Briefly, 293T cells were cotransfected with
GagPol, VSV-G expression plasmid, and plentiCRISPRv2-STAT1 plas-
mids using ViaFect Transfection Reagent (Promega). Supernatant was
harvested 2 d after transfection and added to THP1 cell; transduced bulk
cells were selected with puromycin selection marker. Immunoblotting was
done to ensure STAT1 KO results, and DNA sequencing was performed to
further confirm the results of gene KO. Single guide RNA sequences are
shown in Supplemental Table I. The expression constructs of STAT1 were
generated by cloning the sequence of the coding region into a Flag-tagged
VR1012 expression vector (STAT1 wild type [WT]). Site-directed muta-
genesis of STAT1 (Y701A and S727A) was generated using mutations
primers by Quik Change PCR (TransGen). All constructs were confirmed
by DNA sequencing, and plasmids were prepared using Endo-Free Plasmid
Kits (V). STAT1-KO THP1 cells were differentiated with 0.5 mg/ml of
PMA for 3 h. To remove the residual effect of PMA, the medium was
replaced with complete RPMI 1640 overnight, then transfected with the
plasmids of STAT1 WT and mutation (STAT1-S727A and STAT1-Y701A).
Flow cytometry
Purified monocytes were cultured with HBsAg or HBVcc, resuspended in
staining buffer, and preincubated with FcR blocking reagent (Miltenyi
Biotec) for 15 min at 4˚C. The cells were stained with anti-human CD14-
PE, anti-human CD282 (TLR2) FITC Abs, and incubated for 15 min at 4˚C
in the dark. The cells were washed with staining buffer, then resuspended
in PBS containing 1% paraformaldehyde. For intracellular STAT staining,
cells were first fixed/permeabilized and subsequent STAT staining per-
formed according to the manufacturer’s protocol (Cytofix Buffer and
Permeabilization Buffer III; BD Biosciences). The intracellular Abs in-
cluded STAT1 (pY701) Alexa Fluor 488 (4a; BD Biosciences), STAT1
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(pS727) PE (clone K51-856 [RUO] BD Biosciences). All data were ac-
quired with an LSRII flow cytometer (BD Biosciences) and analyzed with
FlowJo (Tree Star) software (Ashland, OR).
Cytokine measurements
IL-1b, IL-10, and TNF-a were quantified in supernatants using ELISA kits
(R&D Systems) according to the manufacturer’s recommended protocol.
Statistical analysis
Statistical analysis was performed using a two-tail unpaired Student
t test. Correlation coefficient: Pearson correlation analysis was used to
determine R-values. A p value ,0.05 was considered statistically
significant. Statistical analysis and Pearson correlation analysis were
performed using GraphPad Prism 5 software (GraphPad Software, San
Diego, CA).
Results
Peripheral monocytes express lower levels of IFN
signaling/stimulated genes and higher levels of
inflammatory cytokines in CHB patients
Wefirst compared the difference of antiviral and inflammatory gene
expression in monocytes between healthy donors and CHB patients
(Table I). Monocytes were purified to determine the mRNA ex-
pression of IFN signaling/stimulated genes and inflammatory cy-
tokines by qRT-PCR, and the relative fold induction was
normalized to a housekeeping gene (GAPDH). We observed that
the mRNA expression levels of stat1 (Fig. 1A), stat2 (Fig. 1B),
and ch25h (Fig. 1C) were significantly lower in CHB patients than
in healthy individuals. However, the mRNA expression levels of
IL-1b (Fig. 1D), TNF-a (Fig. 1E), and IL-10 (Fig. 1F) in CHB
patients were significantly higher than in healthy individuals. Among
CHB patients, our statistical analysis showed (Supplemental Fig. 1)
that the serum levels of HBV DNA and HBsAg correlate negatively
with the expression levels of stat1, stat2, and ch25h positively with
the expression levels of IL-1b, TNF-a, and IL-10 in monocytes. IL-10
correlates negatively with the expression levels of stat1, stat2, and
ch25h. These results indicate that the inflammatory cytokines (IL-10)
may inhibit the expression of IFN signaling/stimulated genes in
monocytes of CHB patients.
HBV and IFN-a inversely modulate ISGs expression
of monocytes
Next, we investigated HBVeffect on the antiviral gene expression.
Purified monocytes from healthy donors were cultured with in-
creasing concentrations of HBsAg (0, 0.2, 2, 20 mg/ml), HBVcc
(0, 105, 106, 107 copies/ml), or IFN-a (0, 1, 10, 100 ng/ml) using
HSA, the supernatant of non-HBV transfected cells (HepG2), and
vehicle of IFN-a as controls, respectively. The mRNA expression
levels of stat1, stat2, and ch25h were examined by qRT-PCR, and
the relative fold induction was normalized to HSA, HepG2,
or vehicle of IFN-a. We observed that both HBsAg and HBVcc
caused a dose-dependent decrease in expression of stat1 (Fig. 2A),
stat2 (Fig. 2B), and ch25h (Fig. 2C); IFN-a induced a dose-
dependent increase in the expression of stat1 (Fig. 2D), stat2
(Fig. 2E), and ch25h (Fig. 2F). A total of 107 copies/ml of HBVcc,
20 mg/ml of HBsAg, and 10 ng/ml of IFN-a significantly modu-
lated expression of these genes and were used as the standard
FIGURE 1. Monocytes express lower levels of IFN signaling/stimulated genes and higher levels of inflammatory cytokines on chronic HBV infection.
Monocytes were purified from PBMC of 30 healthy individuals (HC) and 36 CHB patients. The mRNA expression levels of stat1 (A), stat2 (B), ch25h (C),
IL-1b (D), TNF-a (E), and IL-10 (F) were determined by qRT-PCR. Error bars represent the SD. *p , 0.05, **p , 0.01, ***p , 0.001.
Table I. Characteristics of study population
Clinical Data
Healthy Controls
(n = 30)
Chronic HBV
Patients
(n = 36)
Sex (male/female) 16/14 19/17
Age (y) 35.3 6 9.9 34.47 6 14.13
ALT (U/l) 32.6 6 5.5 391.4 6 319.7
HBsAg (IU/ml) Negative 8441.5 6 4598.5
HBeAg (S/CO) Negative 173.2 6 311.3
HBeAb (S/CO) Negative 11.6 6 15.5
HBV DNA (log10 IU/ml) Negative 6.6 6 1.1
Data are shown as average 6 SD.
HBeAb, HBV e Ab; S/CO, signal to cutoff ratio.
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concentrations in the following experiments. Although HBVcc
or HBsAg were added into monocytes cultured with IFN-a, both
HBsAg and HBVcc significantly inhibited IFN-a–induced
mRNA expression levels of stat1 (Fig. 2G), stat2 (Fig. 2H), and
ch25h (Fig. 2I). Also, cells were collected for RNAseq. Self-
organizing heat maps confirmed that HBsAg and HBVcc
inhibited IFN-a–induced ISG expression (e.g., CH25H, TRIM6,
TRIM58, APOBEC3B, APOBEC3D, STAT1, STAT2, etc.
Supplemental Fig. 2A).
HBV induces inflammatory response of monocytes via
TLR2/MyD88/NF-kB signaling pathway
We further investigated whether HBV has direct effects on the
inflammatory response of monocytes, which might account for the
abnormalities of monocytes from CHB patients. Fresh monocytes
from healthy donors were purified and cultured with increasing
concentrations of HBsAg or HBVcc. As expected, both HBsAg
(0, 0.2, 2, 20 mg/ml) and HBVcc (0, 105, 106, 107 copies/ml)
caused a dose-dependent increase in mRNA expression and se-
cretion of IL-1b (Fig. 3A), TNF-a (Fig. 3B), and IL-10 (Fig. 3C).
To determine if HBV activates MyD88/NF-kB signaling in
monocytes, the protein expression of MyD88, TRAF6, and
NFkB1, and IkBa phosphorylation was detected by Western blot.
As shown in Fig. 3D, both HBsAg and HBVcc also induced the
protein expression of MyD88, TRAF6, and promotes IkBa
phosphorylation and IkBa degradation compared with mock
control (HSA and the supernatant of HepG2 cell). Moreover, when
monocytes were treated with the inhibitor of NF-kB (BAY-11-
7085) and cultured with HBVcc or HBsAg, we observed that
BAY-11-7085 inhibited HBsAg- and HBVcc-induced production
of IL-1b, TNF-a, and IL-10 (Fig. 3E).
Previous reports showed that TLR2 expression of monocytes
was reduced in patients with HBeAg-positive chronic HBV in-
fection but increased in HBeAg-negative CHB, compared with
FIGURE 2. HBV and IFN-a inversely modulate ISGs’ expression of monocytes. Purified monocytes from healthy donors (n = 8) were cultured with
increasing concentrations of HBsAg (0, 0.2, 2.0, 20.0 mg/ml) or HBVcc (0, 105, 106, 107 copies/ml) or IFN-a (0, 1, 10, 100 ng/ml) for 12 h. Cells were
collected to assay the mRNA expression of stat1, stat2, and ch25h by qRT-PCR (A–F). Purified monocytes from healthy donors were cultured with or
without IFN-a (10 ng/ml) in presence of HBsAg (20 mg/ml) or HBVcc (107 copies/ml). Cells were collected to assay the mRNA expression of (G) stat1,
(H) stat2, and (I) ch25h by qRT-PCR. Error bars represent the SD. *p , 0.05, **p , 0.01, ***p , 0.001.
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controls (28). In our study population, these findings were con-
firmed as Fig. 4A. We thus investigated whether HBsAg is dif-
ferent from HBeAg in its ability to upregulate TLR2 expression
of monocytes, resulting in inflammatory cytokines production.
Purified monocytes from healthy donors were cultured with
HBsAg and HBVcc (without encoded protein contamination),
and we observed that both HBsAg and HBVcc upregulated
TLR2 expression of monocytes on both mRNA (Fig. 4B) and
protein level (Fig. 4C) but not other TLRs compared with HSA
and HepG2 controls. We thus tested if HBV-induced inflamma-
tory response is mediated via TLR2 signaling. Purified mono-
cytes were pretreated with anti-TLR2 or anti-TLR4 Ab and then
stimulated with HBsAg or HBVcc. We observed that blockade of
TLR2 significantly inhibited HBsAg- and HBV-induced cytokine
expression and secretion of IL-1b (Fig. 4D), TNF-a (Fig. 4E),
and IL-10 (Fig. 4F).
HBV and IFN-a, respectively, induce inflammatory and
antiviral gene by differential STAT1 phosphorylation
STAT1 is a key component of the transcription factor complex in
the IFN signaling pathway (29) and also plays a role in the in-
flammatory response (30). We investigated STAT1 phosphoryla-
tion in response to HBV and IFN-a. Purified monocytes were
treated with IFN-a and/or HBVcc/HBsAg, and the effect of HBV
and IFN-a on the phosphorylation of STAT1–Tyrosine 701 and
STAT1–Serine 727 was determined by Western blot. We observed
that both HBsAg and HBVcc activated STAT1 Serine 727 phos-
phorylation but not STAT1 Tyrosine 701 phosphorylation com-
pared with mock (Fig. 5A). IFN-a activated STAT1 Tyrosine 701
phosphorylation and CH25H protein expression, and both HBsAg
and HBVcc inhibited IFN-a–induced STAT1 Tyrosine 701 phos-
phorylation and CH25H protein expression compared with IFN-a
(Fig. 5B). Further, we found that IFN-a induced STAT2 protein
FIGURE 3. HBV activates MyD88/TRAF6/NF-kB signaling. Purified monocytes from healthy HBV-negative blood donors (n = 6) were cultured in the
presence of increasing concentrations of HBsAg (0, 0.2, 2.0, 20.0 mg/ml) or HBVcc (0, 105, 106, 107 copies/ml) for 24 h; the mRNA expression level and
production of IL-1b (A), TNF-a (B), and IL-10 (C) were determined by real-time RT-PCR and ELISA, and the relative fold induction was normalized to
HSA or HepG2. Purified monocytes from healthy HBV-negative blood donors were cultured with HBsAg (20 mg/ml) or HBVcc (107 copies/ml) for 12 h.
Western blots were performed for the expression of MyD88, TRAF6, IkBa, and IkBa phosphorylation. b-actin was used as loading control (D). Purified
monocytes were treated with 5 mM BAY-11-7085 in the presence of HBsAg (20 mg/ml) or HBVcc (107 copies/ml) for 24 h; cytokine production of IL-1b,
TNF-a, and IL-10 were detected by ELISA (E). Error bars represent the SD. *p , 0.05, **p , 0.01, ***p , 0.001.
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expression and phosphorylation, but HBsAg and HBVcc did not
inhibit IFN-a–induced STAT2 (Y690) phosphorylation. We next
constructed the plasmids encoding STAT1 WT and two mutations
(STAT1-S727A and STAT1-Y701A) and then transfected them into
STAT1-deficient THP1 cells. The cells were stimulated with IFN-a
or HBsAg. The results showed that HBsAg induced the phosphor-
ylation of STAT1–Serine 727 and IL-1b expression in STAT1 WT
transfected cells, but the mutation STAT1-S727A shut down HBsAg-
induced phosphorylation of STAT1–Serine 727 and IL-1b expres-
sion (Fig. 5C). Conversely, IFN-a induced the phosphorylation of
FIGURE 4. HBV induces inflammatory cytokines production via TLR2 signaling. Monocytes were purified from PBMC of 18 healthy individuals (HC),
13 HBeAg-negative CHB and 23 HBeAg-positive CHB. The mRNA expression levels of TLR2 were determined by real-time RT-PCR (A). Purified
monocytes from healthy HBV-negative blood donors (n = 10) were cultured with HBsAg (20.0 mg/ml) or HBVcc (107 copies/ml) for 12 h, the mRNA
expression level of TLR1-TLR10 were determined by real-time RT-PCR and agarose gel electrophoresis (B), and cell surface expression of TLR2 were
analyzed by flow cytometry (C). Purified monocytes were pretreated with anti-TLR2 Ab (0.5 mg/ml) or anti-TLR4 Ab (5 mg/ml) for 1 h, and then stimulated
with HBsAg or HBVcc for 24 h, the cytokine expression and production of IL-1b (D),TNF-a (E) and IL-10 (F) were determined by real-time RT-PCR and
ELISA, the relative fold induction was normalized to HSA or HepG2. Error bars represent the SD. *p , 0.05, **p , 0.01.
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STAT1–Tyrosine 701 and CH25H expression in STAT1 WT trans-
fected cells, but the mutation of STAT1-Y701A–shut off IFN-a in-
duced the phosphorylation of STAT1–Tyrosine 701 and CH25H
expression (Fig. 5D). These results indicate that HBV induces the
inflammatory response by activation of STAT1–Serine 727 phos-
phorylation, whereas IFN-a induces the antiviral effect by activation
of STAT1–Tyrosine 701 phosphorylation.
Given that HBV induces the production of IL-1b, TNF-a, and
IL-10 and inhibits IFN-a–induced mRNA expression of stat1,
stat2, and ch25h in monocytes, we next tested if HBV inhibits
IFN-a–induced IFN signaling gene expression through inflam-
matory cytokine production. The Abs were respectively added into
monocytes cultured with IFN-a in the presence of HBVcc or
HBsAg to neutralize IL-10, IL-1b, and TNF-a. We observed that
FIGURE 5. HBVactivates STAT1-ser727 phosphorylation and inhibits IFN-a–induced STAT1-Tyr701 phosphorylation. Purified monocytes from healthy
donors (n = 6) were stimulated for 12 h with HBsAg (20 mg/ml) or HBVcc (107 copies/ml) (A) or with IFN-a (10 ng/ml) in the presence of HBsAg
(20 mg/ml) or HBVcc (107 copies/ml) (B). Western blots were performed for STAT1, STAT2, CH25H expression and phosphorylation of STAT1-
Tyr701, STAT1-ser727, and STAT2-Tyr690; b-actin was used as loading control. STAT1 KO THP1 cells were seeded in 24-well plate and differentiated
with 0.5 mg/ml of PMA for 3 h. To remove the residual effect of PMA, the medium was replaced with complete RPMI 1640 overnight, then transfected
with STAT1-WT, STAT1-S727A, or STAT1-Y701A expression plasmids as indicated. After 24 h, Cells were treated with HBsAg (20 mg/ml) or HSA for
12 h, Cells were collected to examine phosphorylation of STAT1-ser727 and the mRNA expression levels of IL-1b by Western blot and qRT-PCR,
respectively (C). Cells were treated with IFN-a (10 ng/ml) or vehicle for 12 h; phosphorylation of STAT1-Tyr701 and the mRNA expression levels
of CH25H were detected as well (D) (n = 3). Purified monocytes were treated with neutralization Abs of IL-10 (0.5 mg/ml), IL-1b (1 mg/ml), or
TNF-a (0.5 mg/ml) for 1 h and then stimulated with IFN-a (10 ng/ml) in the presence of HBsAg (20 mg/ml) or HBVcc (107 copies/ml); cells were
collected to assay the mRNA expression of (E) stat1, (F) stat2, and (G) ch25h by qRT-PCR. Error bars represent the SD. *p , 0.05, **p , 0.01,
***p , 0.001.
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neutralization of IL-10 but not IL-1b or TNF-a partially restored
the mRNA expression levels of IFN-a–induced stat1 (Fig. 5E),
stat2 (Fig. 5F), and ch25h (Fig. 5G), which were inhibited by
HBsAg or HBVcc. These data suggest that HBV-induced IL-10
production of monocytes partially inhibited IFN-a–induced ISG
expression in an autocrine manner.
2-NP rescues IFN signaling and inhibits the inflammatory
cytokines production
As an enhancer of STAT1, 2-NP has been reported to specifically
enhance STAT1-dependent gene expression and the induction of
an endogenous STAT1 target gene by specifically prolonging the
tyrosine phosphorylation of STAT1 (31), and we confirmed this in
Supplemental Fig. 3B. We thus investigated whether 2-NP affects
IFN-a–induced IFN signaling gene expression and HBV-induced
inflammatory cytokines. Purified monocytes were pretreated with
increasing concentrations of 2-NP for 1 h and then stimulated with
HBsAg or HBVcc in the presence or absence of IFN-a. The results,
shown as Supplemental Fig. 3C, were that 2-NP causes a dose-
dependent increase of ch25h expression but not stat1 nor stat2. A
total of 45 mmol/l of 2-NP was used as the optimal concentration in
the following experiments. We further observed that 2-NP rescues
the inhibition of STAT1-dependent gene (ch25h) expression by
HBV (Fig. 6C) but not STAT1 (Fig. 6A) or STAT2 (Fig. 6B). 2-NP
also inhibits inflammatory cytokines in monocytes, including IL-1b
(Fig. 6D), TNF-a (Fig. 6E), and IL-10 (Fig. 6F). These results
imply that the combination of an agent that acts like 2-NP with
IFN-a warrants careful consideration as a potential therapeutic
strategy in chronic HBV infection.
Discussion
Circulating monocytes are a clinically accessible cell population
that differentiates into tissue macrophages resident or dendritic
cells and may directly be modified during the natural course of viral
infection (32). Monocytes are key mediators of inflammatory and
antiviral response in viral infection (33). In this study, we observed
the lower expression of IFN signaling/stimulated genes and higher
expression of inflammatory cytokines genes in peripheral mono-
cytes from CHB patients (Fig. 1), suggesting mutual antagonism
between the inflammatory and antiviral response. In addition, the
serum levels of HBsAg and HBV DNA correlate negatively with
IFN signaling/stimulated genes and positively with the expression
of inflammatory cytokines in monocytes. These data imply that
HBsAg and HBV may suppress the antiviral response and induce
the inflammatory response in the monocytes of CHB patients.
To analyze this phenomenon, peripheral blood monocytes from
healthy donors were exposed to HBVand/or IFN-a; we found that
HBsAg/HBV and IFN-a inhibit or induce stat1, stat2, ch25h ex-
pression, respectively, and HBsAg/HBV inhibits IFN-a–induced
stat1, stat2, ch25h expression in monocytes (Fig. 2). To the best of
our knowledge, this is the first description of HBV-impaired an-
tiviral response on monocytes. The nature of innate immunity
induced by HBV remains controversial. One study showed that
HBV cannot activate host innate antiviral responses in the liver
(34), whereas another showed that HBV induces IFN-I and type
III IFN, suggesting that the host can sense the HBV infec-
tion (35–37). At present, these conflicting conclusions are diffi-
cult to reconcile. STAT1 and STAT2 are key components of the
transcription factor complex in the IFN signaling pathways.
FIGURE 6. 2-NP rescues IFN signaling and inhibits the inflammatory cytokines production. Purified monocytes from healthy donors (n = 6) were
pretreated with 2-NP (45 mmol/l) for 1 h, then stimulated with HBsAg (20 mg/ml) or HBVcc (107 copies/ml) and IFN-a (10 ng/ml) for 12 h. Cells were
collected to assay the mRNA expression of (A) stat1, (B) stat2, and (C) ch25h by qRT-PCR, and the relative fold induction was normalized to HSA or
HepG2. The supernatants were collected at 24 h; the productions of IL-1b (D), TNF-a (E), and IL-10 (F) were detected by ELISA. Error bars represent
the SD. *p , 0.05, **p , 0.01, ***p , 0.001.
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The response of immune and nonimmune cells to type I and III
IFNs triggers the formation of heterotrimers containing STAT1,
STAT2, and the IFN regulatory factor 9 (38). STAT1 is the most
essential transcriptional factor involved in the induction of CH25H
(39). As shown previously, CH25H expression in response to viral
infections or IFNs was almost completely abrogated in STAT1-
deficient macrophages (40). HCV-induced CH25H expression
synthesizes 25HC to inhibit HCV RNA replication by preventing
formation of the viral replication factory in human hepatocytes
(41). IFN-a induces the transfer of resistance to HBV from non-
permissive liver nonparenchymal cells to permissive hepatocytes
via exosomes, which were rich in molecules with antiviral activity
(42). IFN-a induces CH25H expression in monocytes, and its
product, 25HC, may inhibit HBV replication primarily at the level
of transcription or RNA translation in hepatocytes. Our data fur-
ther reveal that HBV and HBsAg inhibit IFN-a–induced CH25H
expression of monocytes, which may be relevant to the poor re-
sponse rate of IFN-based clinical therapy in chronic HBV patients.
These findings show that the application of either HBVor HBsAg
reproduces the effects of in vivo HBV infection in terms of IFN
signaling/stimulated genes such as stat1, stat2, ch25h.
HBV is well known to subvert monocyte function, but molecular
mechanisms are not fully defined. TLRs are key sensors in HBV
recognition (43, 44). TLR2 detects several microbial pathogen-
associated molecular patterns either in its homodimer form or in
a heterodimer with TLR1 or TLR6 and subsequently activates
TRAF6 and NF-kB in a MyD88-dependent manner (45). In this
study, we found that both HBsAg and HBVcc upregulated TLR2
expression, whereas blockade of TLR2 suppressed the HBV-
induced inflammatory response (Fig. 4), confirming the specific-
ity of the effect. Because the inflammatory response was likely to
be driven via NF-kB (46, 47), we confirmed that HBV induces
the increased expression of MyD88, TRAF6, and NFkB1, pro-
motes IkBa phosphorylation, and that inhibition of NF-kB
suppressed HBV-induced inflammatory cytokine production
(Fig. 3). We consistently found that serum from CHB patients
significantly induced inflammatory cytokines production and
inhibited IFN-a–induced stat1, stat2, ch25h expression in mono-
cytes compared with serum from healthy individuals (Supplemental
Fig. 2B, 2C), Therefore we argue the NF-kB pathway was engaged.
Our findings identify a novel mechanism by which HBV induces
inflammatory response via TLR2/MyD88/NF-kB signaling pathway
in peripheral monocytes.
Previous studies have demonstrated that TLR2, TLR4, and TLR9
induce STAT1-Ser727 phosphorylation (48, 49) and that TLR-
induced STAT1-Ser727 phosphorylation is independent of IFN-I
production (30). TRAF6 appears to have a critical role not only
in transducing the canonical MyD88 signal transduction pathway
leading to NF-kB nuclear translocation but also interacting with
components of the JAK/STAT pathway. TRAF6 may act as the
proximal bridge for the recruitment of the STAT1 serine kinase
into the MyD88 canonical pathway to NF-kB activation (30).
In the current study, we found that HBV activates the STAT1-Ser727
phosphorylation and inhibits IFN-a–induced STAT1-Tyr701 phos-
phorylation in monocytes. However, HBV polymerase was shown to
suppress IFN-a–induced STAT1-Ser727 phosphorylation in human
hepatic cell lines (50), suggesting that HBV manipulates monocytes
in a way distinct from its effects on hepatocytes. It has been reported
that HBV represses IFN/JAK/STAT signaling by attenuating the
phosphorylation and nucleus translocation of STAT1 to facilitate
HBV replication (51). We consistently found that the expression level
of STAT1-Ser727 was significantly higher in monocytes from CHB
patients than those from healthy individuals, but the expression level of
STAT1-Tyr701 was not significantly different (Supplemental Fig. 3A).
Moreover, we also identified that HBV inhibits IFN-a–induced
stat1, stat2, ch25h expression via an autocrine effect of secreted
IL-10 partially (Fig. 5). These in vitro data reproduce our in vivo
findings, which showed IL-10 correlates negatively with the
expression of IFN signaling/stimulated genes in CHB patients. It
has been demonstrated that HBsAg stimulates monocytes to
produce IL-10, which then suppress IFN-a production by plas-
macytoid dendritic cells (10). IFN-a increases the sensitivity of
monocytes to IL-10 by upregulating the expression of IL-10R1,
and IL-10 induces a higher level of STAT3 phosphorylation in
IFN-primed cells (52). These findings suggest that HBV and
IFN-a differentially target the phosphorylation of STAT1 to
determine the inflammatory response and antiviral effect in
monocytes and that HBV induces the antagonism between in-
flammation and antiviral immunity in an IL-10–dependent,
partially autocrine manner.
It remains controversial whether chronically HBV-infected
patients have impaired immunity to infection with viruses
(e.g., influenza A virus, Sendai virus, etc.) that induce strong
IFN-I responses. Luangsay et al. (53) reported that HBV can
inhibit the innate response triggered by a super infection with
Sendai virus in dHepaRG cells. However, another studies
showed that Sendai virus and poly I:C–induced IFN-I responses
and ISG expression were not suppressed in HBV-infected liver
(54–56). Moreover, although HBV infection may not induce any
IFN-I response in hepatocytes, they nevertheless activate in-
flammatory response of macrophages (56). In our study we in-
vestigated that HBV manipulated IFN signaling in human
monocytes, not hepatocytes. In exposure of blood monocytes to
poly I:C and HBVcc/HBsAg, we found that poly I:C induced
stat1, stat2, ch25h, and IFN-b mRNA expression, whereas
HBsAg and HBVcc inhibited the effect of poly I:C (H. Song and
Z. Tu, unpublished observations). However, whether it reflects
the impaired immunity to infection with viruses (e.g., influenza
A virus, Sendai virus, etc.) in chronic HBV-infected patients
needs to be further explored.
In summary, we showed that HBsAg and HBVcc have similar
effects in inducing both proinflammatory and IL-10 responses but
inhibiting the induction of ISGs and that these effects are likely in-
tegrated through an effect of HBVon STAT1 phosphorylation. In the
presence of HBV, STAT1 phosphorylation on tyr701 is impaired, but
phosphorylation on ser727 is increased. This suggests HBV may
increase the abundance of signaling molecules in the NF-kB pathway
but conversely decreases the abundance of STAT1 and STAT2 as well
as ISGs. These data argue that HBV impairs STAT1/2–mediated
signaling at multiple levels, subverting host antiviral immunity. We
further conclude that monocytes display two distinct and mutually
antagonistic modes of activation in response to HBV and IFN-a
and that HBV imposes a bias, which emphasizes inflammation
at the expense of IFN-a– induced antiviral defense.
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